What the Research Says
A large meta-analysis of 38 randomized controlled trials involving 149,051 participants found that omega-3 fatty acids reduced cardiovascular mortality by 7% (RR 0.93, 95% CI 0.88–0.98), non-fatal myocardial infarction by 13% (RR 0.87, 95% CI 0.81–0.93), and major adverse cardiovascular events (MACE) by 5% (RR 0.95, 95% CI 0.92–0.98) [1]. Another meta-analysis of 14 trials with 135,291 subjects confirmed reductions in MACE (RR 0.95, 95% CI 0.91–0.99), cardiovascular death (RR 0.94, 95% CI 0.89–0.99), and myocardial infarction (RR 0.86, 95% CI 0.79–0.93) [4].
The benefits appear stronger with EPA monotherapy than with combined EPA+DHA. In the meta-analysis, EPA alone reduced cardiovascular mortality by 18% (RR 0.82, 95% CI 0.68–0.99) and non-fatal MI by 28% (RR 0.72, 95% CI 0.62–0.84), whereas EPA+DHA combinations showed smaller and sometimes non-significant effects [1]. The REDUCE-IT trial, using high-dose icosapent ethyl (4 g/day purified EPA), demonstrated a remarkable reduction in cardiovascular events in statin-treated patients with hypertriglyceridemia [6][7].
Omega-3 supplementation also reduces triglyceride levels and has pleiotropic effects including anti-inflammatory actions, improved plaque stability, and modulation of cellular membranes [5][7]. Doses of 0.8–1.2 g/day were found to be more effective than lower or higher doses for reducing MACE, cardiovascular death, and MI [4].
Caveats and Risks
Despite overall benefits, omega-3 supplementation is associated with an increased risk of atrial fibrillation (RR 1.26, 95% CI 1.08–1.48) and, with EPA monotherapy, a higher risk of total bleeding (RR 1.49, 95% CI 1.20–1.84) [1]. These risks should be weighed against cardiovascular benefits, especially in patients predisposed to bleeding or arrhythmias.
Results across trials have been inconsistent, partly due to differences in dosing, formulation (EPA vs. EPA+DHA), and background statin therapy [2][3]. Some trials using lower doses (<1 g/day) or combined EPA+DHA failed to show significant benefits, while high-dose EPA trials have been more positive [2][7]. The STRENGTH trial, which used a combination EPA+DHA formulation, did not replicate the positive results of REDUCE-IT, highlighting the importance of formulation and dose [7].
本文引用的文献
Effect of omega-3 fatty acids on cardiovascular outcomes: A systematic review and meta-analysis
In 149,051 participants across 38 RCTs, omega-3 reduced cardiovascular mortality by 7% (RR 0.93), non-fatal MI by 13% (RR 0.87), and MACE by 5% (RR 0.95), with greater reductions from EPA monotherapy than EPA+DHA, but increased atrial fibrillation (RR 1.26) and bleeding (RR 1.49 with EPA).
An Update on Omega-3 Polyunsaturated Fatty Acids and Cardiovascular Health
Discordant trial results may be explained by insufficient omega-3 dosing (<1 g/day EPA+DHA) and aggressive background therapy; high-dose EPA (4 g/day) showed remarkable CVD event reduction.
Update on Omega-3 Polyunsaturated Fatty Acids on Cardiovascular Health
Omega-3 fatty acids reduce very high triglyceride levels, hospitalizations, and CVD mortality, with benefits extending to autoimmune, infectious, and kidney diseases.
Omega-3 Fatty Acid Supplementation and Coronary Heart Disease Risks: A Meta-Analysis of Randomized Controlled Clinical Trials
In 135,291 subjects across 14 RCTs, omega-3 reduced MACE (RR 0.95), cardiovascular death (RR 0.94), and MI (RR 0.86), with 0.8–1.2 g/day being the most effective dose range.
Cardiovascular Impact of Nutritional Supplementation With Omega-3 Fatty Acids
Marine-derived omega-3 PUFAs reduce triglycerides and have pleiotropic effects; prescription EPA ethyl ester shows benefit for ASCVD event reduction in selected populations.
Omega-3 fatty acids for cardiovascular event lowering
Icosapent ethyl (purified EPA) has compelling evidence for lowering residual CV risk in hypertriglyceridemic patients on statins, while other omega-3 formulations have shown mixed results.
Omega-3 and cardiovascular prevention – Is this still a choice?
High-dose icosapent ethyl (EPA) is a valuable approved option to reduce ASCVD risk, supported by REDUCE-IT, while the STRENGTH trial with EPA+DHA did not show similar benefits.